New Market Report: Metastatic Hormone Refractory Prostate Cancer - Pipeline Review, H2 2012
Global Markets Direct's, 'Metastatic Hormone Refractory Prostate Cancer - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Hormone Refractory Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory Prostate Cancer. Metastatic Hormone Refractory Prostate Cancer - Pipeline Review, Half Year is built using data and information sourced...
View full press release